enGene price target lowered to $30 from $33 at Oppenheimer

Oppenheimer lowered the firm’s price target on enGene (ENGN) to $30 from $33 and keeps an Outperform rating on the shares. The firm notes the company announced that it plans to present updated results from the pivotal cohort of its ongoing LEGEND trial in NMIBC at a medical conference this spring – Oppenheimer presumes the annual AUA meeting in mid-May. The firm caught up with management, who indicated that the content will most likely feature six-month complete response rates, as well as CR rates at any time, from the vast majority of this cohort’s subjects. Oppenheimer looks toward the second half of 2026 for 12-month data as well as potential BLA submission.